No Data
Zhejiang Yatai Pharmaceutical (002370.SZ): The controlling shareholder Fubon Group has completed the shareholding of 2.01%.
Zhejiang Yatai Pharmaceutical (002370.SZ) announced that up to the disclosure date of this announcement, the controlling shareholder of the company, Fubon Group, has accumulated an additional 12.27 million shares of the company through the Shenzhen Stock Exchange's centralized bidding trading system, with a total additional investment of 36,364,912.15 yuan, accounting for 2.01% of the total share capital of the company. The shareholding plan has been fully implemented upon completion.
Zhejiang Yatai Pharmaceutical: 2024 Interim Performance Forecast
Zhejiang Yatai Pharmaceutical (002370.SZ): Net income is expected to decrease by 67.12%-77.23% in the first half of the year.
Zhejiang Yatai pharmaceutical (002370.SZ) announced its performance forecast for the first half of 2024. The net income attributable to the shareholders of the listed company during the reporting period is expected to be between 4.5 million and 6.5 million yuan, a decrease of 67.12% - 77.23% compared to the same period last year; the net income after deducting non-recurring gains and losses is expected to be a loss of 6.8 million to 8.8 million yuan, a decrease of 73.99% - 79.90% compared to the same period last year; the revenue is expected to be 220 million to 230 million yuan; the basic earnings per share is expected to be between 0.0074 yuan/share and 0.0107 yuan/share. The company's net income attributable to shareholders of the listed company for the current period.
The controlling shareholder of Asia Pacific Pharmaceutical (002370.SZ) increased its cumulative shareholding by 2.01%
Asia Pacific Pharmaceutical (002370.SZ) issued an announcement. The company received Ning, the controlling shareholder of the company, on May 6, 2024...
Asia Pacific Pharmaceutical (002370.SZ): Net loss of 2.9984 million yuan in the first quarter
Gelonghui, April 26 | Asia Pacific Pharmaceutical (002370.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 113 million yuan, down 8.80% from the previous year; net profit attributable to shareholders of listed companies - RMB 29.984 million; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 2,211,300; and basic earnings per share - 0.0049 yuan.
Asia Pacific Pharmaceutical (002370.SZ) reported 2023 annual results, with a net loss of 11.877 million yuan, which narrowed the year-on-year loss
Asia Pacific Pharmaceutical (002370.SZ) released its 2023 annual report. The company achieved operating income of 4 during the reporting period...
Some Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) Shareholders Look For Exit As Shares Take 26% PoundingNo Data
